Alshrari AS

ORCID: 0000-0002-3666-3848 · 1 paper in corpus · active 2021
2021
Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades.
Pharmaceuticals (Basel, Switzerland) ·doi:10.3390/ph14080710

Protein kinase inhibitors (PKIs) are important therapeutic agents. As of 31 May 2021, the United States Food and Drug Administration (USFDA) has approved 70 PKIs. Most of the PKIs are employed to treat cancer and inflammatory diseases. Imat…